Menachem Esq - Brainsway Gen VP
| BWAY Stock | ILA 1,799 50.00 2.70% |
Insider
Menachem Esq is Gen VP of Brainsway
| Phone | (972) 2 582 4030 |
| Web | www.brainsway.com |
Brainsway Management Efficiency
The company has return on total asset (ROA) of (0.0751) % which means that it has lost $0.0751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2021) %, meaning that it generated substantial loss on money invested by shareholders. Brainsway's management efficiency ratios could be used to measure how well Brainsway manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Aron Tendler | Brainsway | N/A | |
| Christopher Jako | Brainsway | 55 | |
| Moria Ankri | Brainsway | 40 | |
| Yvonne Naughton | Compugen | N/A | |
| Rivka Schwartz | Compugen | N/A | |
| Vered RazAvayo | Foresight Autonomous Holdings | 49 | |
| Sivan Scherf | Foresight Autonomous Holdings | 36 | |
| David Lempert | Foresight Autonomous Holdings | 33 | |
| Doron Cohadier | Foresight Autonomous Holdings | 44 | |
| Sivan Scher | Foresight Autonomous Holdings | 32 | |
| Ari Shamiss | Kamada | N/A | |
| Alberto Sessa | Compugen | 61 | |
| Kfir Zilberman | Foresight Autonomous Holdings | 42 | |
| , MBA | Compugen | 52 | |
| Alain Charlois | Foresight Autonomous Holdings | N/A | |
| Henry MD | Compugen | 58 | |
| Hanni Neheman | Kamada | 53 | |
| Lilach Topilsky | Kamada | N/A | |
| Ariella Raban | Kamada | 47 | |
| Yiftach Roth | Brainsway | 53 | |
| Pr Zangen | Brainsway | 54 | |
Management Performance
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0751 |
Brainsway Leadership Team
Elected by the shareholders, the Brainsway's board of directors comprises two types of representatives: Brainsway inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brainsway. The board's role is to monitor Brainsway's management team and ensure that shareholders' interests are well served. Brainsway's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brainsway's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Avner Lushi, Director | ||
| Gavriel Magen, Director | ||
| Rami Itselev, Internal Auditor | ||
| Karen Sarid, Director | ||
| Moria Ankri, VP RD | ||
| Hila Rubinshtein, Managing Director of Quality Control | ||
| Menachem Esq, Gen VP | ||
| Hadar Levy, Senior Vice President, General Manager of North America | ||
| Richard Areglado, VP CFO | ||
| Christopher Jako, President, Chief Executive Officer | ||
| Uri Elmaliach, Director | ||
| Abraham Zangen, Director | ||
| Daniel Azriel, Director | ||
| David Zacut, Chairman of the Board, Interim Chief Executive Officer | ||
| Ety Rayten, External Director | ||
| Pr Zangen, Member CoFounder | ||
| Amit Jino, Clinical Experiment Coordinator | ||
| Yosef Shalom, Director | ||
| Avner Hagai, Co-Chairman of the Board | ||
| Christopher Boyer, Vice President - Global Marketing | ||
| Yiftach Roth, Chief Scientific Officer | ||
| Aron Tendler, Chief Officer | ||
| Ronen Segal, Vice President - Research & Development | ||
| Orly Uri, Director | ||
| Judith Huber, Chief Financial Officer, Senior Vice President |
Brainsway Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Brainsway a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0751 | |||
| Profit Margin | (0.37) % | |||
| Operating Margin | (0.29) % | |||
| Current Valuation | (85.93 M) | |||
| Shares Outstanding | 33.08 M | |||
| Shares Owned By Insiders | 19.83 % | |||
| Shares Owned By Institutions | 1.11 % | |||
| Price To Book | 0.65 X | |||
| Price To Sales | 3.76 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Brainsway Stock
When determining whether Brainsway offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainsway's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainsway Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainsway Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Brainsway. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Brainsway Stock refer to our How to Trade Brainsway Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.